USP5 Promotes Uterine Corpus Endometrial Carcinoma Cell Growth and Migration via mTOR/4EBP1 Activation

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer. 2009;16(2):363–380. doi:10.1677/ERC-08-026619190080
   PubMed Web of Science ®Google Scholar
• Cook C, Stetler C, Petrucelli L. Disruption of protein quality control in parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(5):a009423. doi:10.1101/cshperspect.a00942322553500
   PubMed Web of Science ®Google Scholar
• Tu Y, Chen C, Pan J, Xu J, Zhou ZG, Wang CY. The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol. 2012;5(8):726–738.23071855
   PubMed Web of Science ®Google Scholar
• Wilkinson KD, Tashayev VL, O’Connor LB, Larsen CN, Kasperek E, Pickart CM. Metabolism of the polyubiquitin degradation signal: structure, mechanism, and role of isopeptidase T. Biochemistry. 1995;34(44):14535–14546. doi:10.1021/bi00044a0327578059
   PubMed Web of Science ®Google Scholar
• Ning F, Xin H, Liu J, et al. Structure and function of USP5: insight into physiological and pathophysiological roles. Pharmacol Res. 2020;157:104557. doi:10.1016/j.phrs.2019.10455731756387
   PubMed Web of Science ®Google Scholar
• Dayal S, Sparks A, Jacob J, Allende-Vega N, Lane DP, Saville MK. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem. 2009;284(8):5030–5041. doi:10.1074/jbc.M80587120019098288
   PubMed Web of Science ®Google Scholar
• Meng J, Ai X, Lei Y, et al. USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma. Theranostics. 2019;9(2):573–587. doi:10.7150/thno.2765430809294
   PubMed Web of Science ®Google Scholar
• Liu Y 1, Wang WM, Lu YF, et al. Usp5 functions as an oncogene for stimulating tumorigenesis in hepatocellular carcinoma. Oncotarget. 2017;8(No. 31):50655–50664. doi:10.18632/oncotarget.1690128881591
   PubMedGoogle Scholar
• Ma X, Qi W, Pan H, Yang F, Deng J. Overexpression of USP5 contributes to tumorigenesis in non-small cell lung cancer via the stabilization of beta-catenin protein. Am J Cancer Res. 2018;8(11):2284–2295.30555744
   PubMed Web of Science ®Google Scholar
• Li XY, Wu HY, Mao XF, Jiang LX, Wang YX. USP5 promotes tumorigenesis and progression of pancreatic cancer by stabilizing FoxM1 protein. Biochem Biophys Res Commun. 2017;492(1):48–54. doi:10.1016/j.bbrc.2017.08.04028807830
   PubMed Web of Science ®Google Scholar
• Yang H, Hu T, Hu P, Qi C, Qian L. miR‑143‑3p inhibits endometriotic stromal cell proliferation and invasion by inactivating autophagy in endometriosis. Mol Med Rep. 2021;23(5). doi:10.3892/mmr.2021.11995
   Web of Science ®Google Scholar
• Potu H, Peterson LF, Pal A, et al. Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget. 2014;5(14):5559–5569. doi:10.18632/oncotarget.214024980819
   PubMedGoogle Scholar
• Du Y, Lin J, Zhang R, et al. Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2. Aging. 2019;11(21):9778–9793. doi:10.18632/aging.10242531727867
   PubMedGoogle Scholar
• Kaistha BP, Krattenmacher A, Fredebohm J 1. The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators. Oncotarget. 2017;8(No. 39):66215–66225. doi:10.18632/oncotarget.1988229029505
   PubMedGoogle Scholar
• Alabdullah ML, Ahmad DA, Moseley P, Madhusudan S, Chan S, Rakha E. The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer. J Obstet Gynaecol. 2019;39(4):522–528. doi:10.1080/01443615.2018.153409130712414
   PubMedGoogle Scholar
• Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12(1):71.31277692
   PubMed Web of Science ®Google Scholar
• Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2012;31(19):2373–2388. doi:10.1038/onc.2011.44321996736
   PubMed Web of Science ®Google Scholar
• Ning J, Zhang J, Liu W, Lang Y, Xue Y, Xu S. Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur J Histochem. 2012;56(4):e46. doi:10.4081/ejh.2012.e4623361242
   PubMed Web of Science ®Google Scholar
• Yun SI, Kim HH, Yoon JH, et al. Ubiquitin specific protease 4 positively regulates the WNT/beta-catenin signaling in colorectal cancer. Mol Oncol. 2015;9(9):1834–1851. doi:10.1016/j.molonc.2015.06.00626189775
   PubMed Web of Science ®Google Scholar
• Yang B, Zhang S, Wang Z, et al. Deubiquitinase USP9X deubiquitinates beta-catenin and promotes high grade glioma cell growth. Oncotarget. 2016;7(48):79515–79525. doi:10.18632/oncotarget.1281927783990
   PubMedGoogle Scholar
• Wu X, Liu M, Zhu H, et al. Ubiquitin-specific protease 3 promotes cell migration and invasion by interacting with and deubiquitinating SUZ12 in gastric cancer. J Exp Clin Cancer Res. 2019;38(1):277. doi:10.1186/s13046-019-1270-431234902
   PubMed Web of Science ®Google Scholar
• Ye M, He J, Zhang J, et al. USP7 promotes hepatoblastoma progression through activation PI3K/AKT signaling pathway. Cancer Biomark. 2021:1–11. doi:10.3233/CBM-20005232924983
   PubMed Web of Science ®Google Scholar
• Li N, Zhao Z, Liu P, et al. Upregulation of deubiquitinase USP7 by transcription factor FOXO6 promotes EC progression via targeting the JMJD3/CLU axis. Mol Ther Oncolytics. 2021;20:583–595. doi:10.1016/j.omto.2020.12.00833768140
   PubMed Web of Science ®Google Scholar
• Rong Z, Zhu Z, Cai S, Zhang B. Knockdown of USP8 inhibits the growth of lung cancer cells. Cancer Manag Res. 2020;12:12415–12422. doi:10.2147/CMAR.S25919133293867
   PubMed Web of Science ®Google Scholar
• Sun J, Shen D, Zheng Y, et al. USP8 inhibitor suppresses HER-2 positive gastric cancer cell proliferation and metastasis via the PI3K/AKT signaling pathway. Onco Targets Ther. 2020;13:9941–9952. doi:10.2147/OTT.S27149633116578
   PubMed Web of Science ®Google Scholar
• Jing X, Chen Y, Chen Y, et al. Down-regulation of USP8 inhibits cholangiocarcinoma cell proliferation and invasion. Cancer Manag Res. 2020;12:2185–2194. doi:10.2147/CMAR.S23458632273758
   PubMed Web of Science ®Google Scholar
• Shin S, Kim K, Kim H, et al. Deubiquitylation and stabilization of Notch1 intracellular domain by ubiquitin-specific protease 8 enhance tumorigenesis in breast cancer. Cell Death Differ. 2020;27(4):1341–1354. doi:10.1038/s41418-019-0419-131527799
   PubMed Web of Science ®Google Scholar